GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

  • End date
    Sep 14, 2025
  • participants needed
  • sponsor
Updated on 4 October 2022
metastatic melanoma
systemic therapy
measurable disease
tumor cells
cancer chemotherapy
solid tumour
mucosal melanoma


To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors


This is an open-label, multicenter phase 1/2 study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of GEN1042 administered as a monotherapy or in combination in subjects with metastatic or locally advanced solid tumors. The trial consists of 4 parts: a GEN1042 monotherapy dose escalation (phase 1a), a GEN1042 monotherapy expansion (phase 2a), a combination therapy safety run in (phase 1b), and a combination therapy expansion (phase 2b).

The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined.

Condition Malignant Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
Treatment cisplatin, carboplatin, Gemcitabine, Pembrolizumab, Nab-paclitaxel, 5-FU, GEN1042
Clinical Study IdentifierNCT04083599
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Phase 1a
• Subjects with non-CNS solid tumors that is metastatic or unresectable and for whom there
is no available standard therapy
Phase 2a
• Subjects with a confirmed diagnosis of relapsed or refractory, advanced and/or metastatic
melanoma, NSCLC, or CRC and for whom there is no available standard therapy
Subjects with unresectable Stage III or Stage IV melanoma with no prior systemic
Phase 1b/Phase 2
anticancer therapy for unresectable or metastatic disease. Primary ocular or mucosal
Dose Escalation and Expansion
melanoma is excluded
Measurable disease according to RECIST 1.1
Subjects with Stage IV metastatic or recurrent NSCLC with no prior systemic anticancer
Eastern Cooperative Oncology Group (ECOG) 0-1
therapy, no actionable mutation and tumor demonstrating PD-L1 expression in ≥1% of
tumor cells (TPS ≥1%)
General (all phases)
Subjects with recurrent or metastatic HNSCC with no prior systemic therapy
administered in the recurrent or metastatic setting and tumor demonstrating PD-L1 IHC
CPS ≥1
Subjects with confirmed metastatic PDAC with no previous radiotherapy, surgery
Normal or adequate liver, renal, cardiac and bone marrow function
chemotherapy, or investigational therapy for the treatment of metastatic disease
Must be age ≥ 18 years of age

Exclusion Criteria

Phase 1a/Phase 2a
Phase 1b/Phase 2
Treatment with an anti-cancer agent (within 21 days or after at least 5 half-lives of
General (all phases)
Radiotherapy within 14 days prior to first GEN1042 administration
Subject has an active, known, or suspected autoimmune disease
the drug, whichever is shorter), prior to GEN1042 administration
Toxicities from previous anti-cancer therapies that have not resolved
Has received prior systemic cytotoxic chemotherapy, biological therapy, OR major
surgery within 3 weeks or at least 5 half-lives of the drug (whichever is shorter) of
the first dose of trial treatment
Radiotherapy within 14 days of start of trial treatment or received lung radiation
therapy of > 30 Gy within 6 months of the first dose of trial treatment
History of non-infectious pneumonitis that required steroids or currently has
History of ≥ grade 3 allergic reactions to monoclonal antibody (mAb) therapy
Subject with a condition requiring systemic treatment with either corticosteroids (>10
mg daily prednisone equivalent) or other immunosuppressive medications within 14 days
of first treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note